Current role
Michael J. Newman
Personal wealth note: Equibles reports source-backed professional activity and disclosed compensation; it does not estimate personal net worth.
About Michael J. Newman
Indaptus Therapeutics, Inc. reported in an 8-K filed January 2, 2026 that Michael J. Newman resigned as member of the Board of Directors. Indaptus Therapeutics, Inc. reported in an 8-K filed June 7, 2024 that Michael J. Newman was appointed Class III director, effective June 6, 2024. The proxy statement of Indaptus Therapeutics, Inc. reports total compensation of $718,039 for Michael J. Newman in fiscal 2023, including a base salary of $442,000. Disclosed compensation is on record for 3 fiscal years.
“On December 29, 2025, Michael Newman, Mark Gilbert, and Anthony Maddaluna, members of the Board of Directors (the "Board") of Indaptus Therapeutics, Inc. (the "Company"), each notified the Company of its resignation from the Board effective upon the approval of David Lazar's nominees at the Company's next stockholders' meeting.”
“Based on the foregoing votes, Roger J. Pomerantz, Michael J. Newman and Jeffrey A. Meckler were elected as Class III directors, and Proposals 2 and 3 were approved.”
Summary generated from SEC filings and earnings-call records held by Equibles.
Affiliation history
Recorded current and former roles; source labels appear when available.
-
Current
2021-08-04–present
-
2024-06-06–2026-01-21
Last confirmed by a filing; no departure on record
-
2024-06-06–2026-01-02
-
2021-01-01–2026-01-02
Company network
Recorded roles and call appearances connecting this person to public companies.
Leadership on record at Indaptus Therapeutics, Inc.
Other people whose current roles at this company are on record from its filings.
- David E. Lazar CEO, Chairman
- David Lazar CEO, Chairman, Board Member
- Jeffrey A. Meckler CEO, Board Member
- Jeffrey Meckler CEO
- Junyi Dai CEO, Chairman, Board Member
- Roger J. Pomerantz Chairman, Board Member
- Yu Ding CFO
- Walt A. Linscott COO
- Anthony J. Maddauluna Board Member
- Avraham Ben-Tzvi Board Member
Executive compensation
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2023 | Indaptus Therapeutics, Inc. (INDP) | Chief Scientific Officer | $442,000 | $718,039 |
| 2021 | Indaptus Therapeutics, Inc. (INDP) | Chief Scientific Officer | $291,542 | $851,856 |
| 2020 | Indaptus Therapeutics, Inc. (INDP) | Chief Scientific Officer | $200,000 | $200,000 |
Recent activity
Earnings-call and investor-event appearances, plus filed executive appointments or departures, newest first.